Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
Fang Huang, … , John D. Minna, Ralph J. DeBerardinis
Fang Huang, … , John D. Minna, Ralph J. DeBerardinis
Published October 20, 2020
Citation Information: J Clin Invest. 2021;131(1):e139929. https://doi.org/10.1172/JCI139929.
View: Text | PDF
Research Article Metabolism Oncology

Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer

  • Text
  • PDF
Abstract

MYC stimulates both metabolism and protein synthesis, but how cells coordinate these complementary programs is unknown. Previous work reported that, in a subset of small-cell lung cancer (SCLC) cell lines, MYC activates guanosine triphosphate (GTP) synthesis and results in sensitivity to inhibitors of the GTP synthesis enzyme inosine monophosphate dehydrogenase (IMPDH). Here, we demonstrated that primary MYChi human SCLC tumors also contained abundant guanosine nucleotides. We also found that elevated MYC in SCLCs with acquired chemoresistance rendered these otherwise recalcitrant tumors dependent on IMPDH. Unexpectedly, our data indicated that IMPDH linked the metabolic and protein synthesis outputs of oncogenic MYC. Coexpression analysis placed IMPDH within the MYC-driven ribosome program, and GTP depletion prevented RNA polymerase I (Pol I) from localizing to ribosomal DNA. Furthermore, the GTPases GPN1 and GPN3 were upregulated by MYC and directed Pol I to ribosomal DNA. Constitutively GTP-bound GPN1/3 mutants mitigated the effect of GTP depletion on Pol I, protecting chemoresistant SCLC cells from IMPDH inhibition. GTP therefore functioned as a metabolic gate tethering MYC-dependent ribosome biogenesis to nucleotide sufficiency through GPN1 and GPN3. IMPDH dependence is a targetable vulnerability in chemoresistant MYChi SCLC.

Authors

Fang Huang, Kenneth E. Huffman, Zixi Wang, Xun Wang, Kailong Li, Feng Cai, Chendong Yang, Ling Cai, Terry S. Shih, Lauren G. Zacharias, Andrew Chung, Qian Yang, Milind D. Chalishazar, Abbie S. Ireland, C. Allison Stewart, Kasey Cargill, Luc Girard, Yi Liu, Min Ni, Jian Xu, Xudong Wu, Hao Zhu, Benjamin Drapkin, Lauren A. Byers, Trudy G. Oliver, Adi F. Gazdar, John D. Minna, Ralph J. DeBerardinis

×

Figure 3

IMPDH dependence is a generalizable metabolic liability in MYC-driven tumors.

Options: View larger image (or click on image) Download as PowerPoint
IMPDH dependence is a generalizable metabolic liability in MYC-driven tu...
(A) Upper left, MPA IC50 in 8 ASCL1hi and 6 ASCL1lo cell lines. Others, IC50 of MPA and cisplatin in treatment-naive and chemoresistant pairs. *P < 0.05, **P < 0.01, ***P < 0.001. (B) Xenograft growth, displaying mean and SD for tumor volume (n = 5 mice per group). Arrows indicate start of treatment. ****P < 0.0001. (C) Treatment-naive H1436 xenograft growth. Four cycles of cisplatin (5 mg/kg/w) and etoposide (10 mg/kg/w, EC), or mizoribine (100 mg/kg/d) were administered, starting at the arrow. Individual volumes are displayed. **P < 0.01, ****P < 0.0001. (D and E) H1436 tumors pretreated with cisplatin and etoposide in C, then implanted into new mice. The arrow indicates start of treatment. Individual volumes are displayed. **P < 0.01, ****P < 0.0001. (F) mRNA abundance in parental (P) and chemoresistant (CR) H1436 tumors. Individual data points are shown with mean and SD for 3 replicates of 4 tumors from each group. **P < 0.01, ****P < 0.0001. (G) Survival analysis of LAP-MYC mice treated with saline or mizoribine (n = 12 per group). Dosing began on day 26 after birth (arrow). ****P < 0.0001. (H) Abdominal circumference of LAP-MYC mice treated with saline or mizoribine. Measurements were taken on day 42. ***P < 0.001. (I) Livers of LAP-MYC mice treated with saline or mizoribine. Dissections were performed on day 42. Statistical significance was assessed using a 2-tailed Student’s t test (A, F, and H), 2-way ANOVA with Tukey’s multiple comparisons (B–E), log-rank (Mantel-Cox) test (G). In panels C–E, individual tumors are displayed to demonstrate variability, but statistical comparisons were made with the average and standard error among the groups. Mizoribine treatment of LAP-MYC mice was performed once. All other experiments were repeated twice or more.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts